PF-04171327

DRUG4 trials

Sponsors

Pfizer

Conditions

HealthyHealthy VolunteersRheumatoid Arthritis

Phase 1

A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers

CompletedNCT00812825

PfizerHealthy Volunteers

Start: 2009-01-31End: 2009-07-31Updated: 2009-08-12

Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism

CompletedNCT01199900

Start: 2010-08-31End: 2010-09-30Updated: 2010-12-17

PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions

CompletedNCT01362673

Start: 2011-05-31End: 2011-08-31Updated: 2011-10-07

Phase 2

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

CompletedNCT01393639

PfizerRheumatoid Arthritis

Start: 2011-09-27End: 2014-06-09Updated: 2024-09-04

Related Papers

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study

RMD Open2019-04-0139 citations

Population Pharmacokinetics of Fosdagrocorat (PF‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis

Clinical and Translational Science2017-11-049 citations

Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.

2017-03-2222 citations